Literature DB >> 28006747

Role of protease and protease inhibitors in cancer pathogenesis and treatment.

Ali Eatemadi1, Hammed T Aiyelabegan2, Babak Negahdari3, Mohammad Ali Mazlomi3, Hadis Daraee4, Nasim Daraee4, Razieh Eatemadi5, Esmaeil Sadroddiny6.   

Abstract

Cancer is the second cause of death in 2015, and it has been estimated to surpass heart diseases as the leading cause of death in the next few years. Several mechanisms are involved in cancer pathogenesis. Studies have indicated that proteases are also implicated in tumor growth and progression which is highly dependent on nutrient and oxygen supply. On the other hand, protease inhibitors could be considered as a potent strategy in cancer therapy. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. In this review, we focus on the role of different types of proteases and protease inhibitors in cancer pathogenesis.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Protease; Protease inhibitor; cancer

Mesh:

Substances:

Year:  2016        PMID: 28006747     DOI: 10.1016/j.biopha.2016.12.021

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  23 in total

1.  The constitutive protease release by primary human acute myeloid leukemia cells.

Authors:  Maria Honnemyr; Øystein Bruserud; Annette K Brenner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-19       Impact factor: 4.553

Review 2.  Therapeutic potential of marine peptides in cervical and ovarian cancers.

Authors:  Salman Ahmed; Haroon Khan; Sajad Fakhri; Michael Aschner; Wai San Cheang
Journal:  Mol Cell Biochem       Date:  2021-12-02       Impact factor: 3.396

Review 3.  Cell-extracellular matrix dynamics.

Authors:  Andrew D Doyle; Shayan S Nazari; Kenneth M Yamada
Journal:  Phys Biol       Date:  2022-01-12       Impact factor: 2.583

Review 4.  Plant Kunitz Inhibitors and Their Interaction with Proteases: Current and Potential Pharmacological Targets.

Authors:  Camila Ramalho Bonturi; Ana Beatriz Silva Teixeira; Vitória Morais Rocha; Penélope Ferreira Valente; Juliana Rodrigues Oliveira; Clovis Macêdo Bezerra Filho; Isabel Fátima Correia Batista; Maria Luiza Vilela Oliva
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

Review 5.  Enzyme-responsive smart nanocarriers for targeted chemotherapy: an overview.

Authors:  Hiral Kapalatiya; Yamini Madav; Varunesh Sanjay Tambe; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2021-07-12       Impact factor: 4.617

6.  Impact of Protease Inhibitors on HIV-Associated Kaposi Sarcoma Incidence: A Systematic Review.

Authors:  Elaine Chang; Srikar R Mapakshi; Pamela Mbang; Nader Kim El-Mallawany; Jennifer R Kramer; Donna L White; Elizabeth Y Chiao
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.771

Review 7.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

8.  IR-783 inhibits breast cancer cell proliferation and migration by inducing mitochondrial fission.

Authors:  Pantong Li; Yu Liu; Wuyi Liu; Guobing Li; Qin Tang; Qian Zhang; Faning Leng; Fangfang Sheng; Changpeng Hu; Wenjing Lai; Yali Liu; Min Zhou; Jingbin Huang; Huyue Zhou; Rong Zhang; Yu Zhao
Journal:  Int J Oncol       Date:  2019-06-06       Impact factor: 5.650

9.  Hepatocyte growth factor activator inhibitor type-2 (HAI-2)/SPINT2 contributes to invasive growth of oral squamous cell carcinoma cells.

Authors:  Koji Yamamoto; Makiko Kawaguchi; Takeshi Shimomura; Aya Izumi; Kazuomi Konari; Arata Honda; Chen-Yong Lin; Michael D Johnson; Yoshihiro Yamashita; Tsuyoshi Fukushima; Hiroaki Kataoka
Journal:  Oncotarget       Date:  2018-02-08

10.  Elastin molecular aging promotes MDA-MB-231 breast cancer cell invasiveness.

Authors:  Stéphanie Salesse; Ludivine Odoul; Lise Chazée; Christian Garbar; Laurent Duca; Laurent Martiny; Rachid Mahmoudi; Laurent Debelle
Journal:  FEBS Open Bio       Date:  2018-08-02       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.